{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:15:58Z","timestamp":1787948158073,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jaad.2016.10.042","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T19:01:09Z","timestamp":1483038069000},"page":"670-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents"],"prefix":"10.1016","volume":"76","author":[{"given":"\u0141ukasz","family":"Matusiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Szcz\u0119ch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Bieniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Nowicka-Suszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.10.042_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","article-title":"The prevalence of hidradenitis suppurativa and its potential precursor lesions","volume":"35","author":"Jemec","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2133.2001.04137.x","article-title":"Morbidity in patients with hidradenitis suppurativa","volume":"144","author":"von der Werth","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2340\/00015555-0866","article-title":"Psychophysical aspects of hidradenitis suppurativa","volume":"90","author":"Matusiak","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.10.042_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2016.10.042_bib5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are\u00a0important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib7","series-title":"Hidradenitis suppurativa","first-page":"11","article-title":"Clinical presentation","author":"Poli","year":"2006"},{"key":"10.1016\/j.jaad.2016.10.042_bib8","series-title":"Roenigk and Roenigk's dermatologic surgery: principles and practice","first-page":"623","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach","author":"Hurley","year":"1996"},{"key":"10.1016\/j.jaad.2016.10.042_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/ijd.12550","article-title":"Hidradenitis suppurativa: the role of immune dysregulation","volume":"53","author":"Kelly","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2133.2009.09430.x","article-title":"Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study","volume":"162","author":"van der Zee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review","volume":"146","author":"Hsiao","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.12104","article-title":"Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review","volume":"168","author":"Blok","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/13547500903075218","article-title":"Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging","volume":"14","author":"Matusiak","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.jaad.2016.10.042_bib15","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bjd.12234","article-title":"Myeloid marker S100A8\/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?","volume":"168","author":"Wieland","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2340\/00015555-2061","article-title":"Chitinase-3-like protein 1 (YKL-40): novel biomarker of hidradenitis suppurativa disease activity?","volume":"95","author":"Matusiak","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.10.042_bib17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaad.2015.08.052","article-title":"Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS)","volume":"73","author":"Hessam","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumor necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumor necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.10.042_bib20","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jaad.2015.07.053","article-title":"Treatment of hidradenitis suppurativa with biologic medications","volume":"73","author":"Lee","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2016.10.042_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjd.14703","article-title":"The many faces of IL-17 in inflammatory skin diseases","volume":"175","author":"Speeckaert","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib22","first-page":"828","article-title":"Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis","volume":"29","author":"Romero-Sanchez","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcma.2012.05.006","article-title":"Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis","volume":"75","author":"Chen","year":"2012","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jaad.2016.10.042_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","article-title":"IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities","volume":"54","author":"Jansen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2016.10.042_bib26","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1002\/ibd.21816","article-title":"Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis","volume":"17","author":"Fonseca-Camarillo","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2016.10.042_bib27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3892\/ijmm.2013.1287","article-title":"Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis","volume":"31","author":"Dong","year":"2013","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jaad.2016.10.042_bib28","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/MIB.0b013e3182a563cb","article-title":"Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease","volume":"19","author":"Ohman","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2016.10.042_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11596-016-1538-2","article-title":"Expression and clinical significance of IL-17 and IL-17 receptor in ulcerative colitis","volume":"36","author":"Zhang","year":"2016","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.jaad.2016.10.042_bib30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.10.042_bib31","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.10.042_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clindermatol.2013.11.006","article-title":"Hidradenitis suppurativa (acne inversa) as a systemic disease","volume":"32","author":"Dessinioti","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib33","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/bjd.13122","article-title":"Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities","volume":"171","author":"Crowley","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaad.2013.11.014","article-title":"The prevalence of metabolic syndrome in patients with hidradenitis suppurativa","volume":"70","author":"Gold","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.10.042_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000371877","article-title":"Decreased number of circulating endothelial progenitor cells in hidradenitis suppurativa patients","volume":"230","author":"Matusiak","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2016.10.042_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2009.07.152","article-title":"Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice","volume":"388","author":"van Es","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaad.2016.10.042_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000314626","article-title":"Emerging role of IL-17 in atherosclerosis","volume":"2","author":"Chen","year":"2010","journal-title":"J Innate Immun"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:40:47Z","timestamp":1759272047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216310180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0190962216310180"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.10.042","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727162855.793542998","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}